Guardian Science Weekly

Are we finally nearing a treatment for Alzheimer’s?

Loading player...
Back in November, researchers hailed the dawn of a new era of Alzheimer’s therapies. After decades of failure, a clinical trial finally confirmed that a drug, lecanemab, was able to slow cognitive decline in patients with early stages of the disease. The result may have been modest – a reduction in the decline in patients’ overall mental skills by 27% over 18 months – but it could not be more significant in the journey towards better understanding and treating the disease. Ian Sample speaks to Prof Nick Fox about the clinical trial results, if this could be the first of many new Alzheimer’s therapies, and whether we could one day see a cure.. Help support our independent journalism at theguardian.com/sciencepod
29 Dec 2022 English United Kingdom Science · Nature

Other recent episodes

Can a name change transform PCOS outcomes for women?

After more than a decade of global consultation, polycystic ovary syndrome – which affects as many as one in eight women – has been renamed. The condition is caused by high levels of androgens, which can lead to symptoms such as excess hair, weight gain and irregular periods. To understand…
21 May 16 min

Ebola outbreak: what do we know and can it be contained?

An outbreak of Ebola has emerged in the Democratic Republic of Congo and Uganda, which has led to nearly 400 confirmed cases and more than 100 deaths. To find out how the outbreak might have begun, what authorities can do to contain it and why this outbreak is causing particular…
18 May 13 min

Hantavirus update, Pentagon’s UFO files, can art slow biological ageing?

Madeleine Finlay sits down with co-host and science editor Ian Sample to discuss three eyecatching stories from the week, including an update on hantavirus. Also on the agenda is the Pentagon’s release of a tranche of never before seen documents relating to UFOs, and a study looking at the link…
14 May 21 min

Trump is backing psychedelic research: here’s why

Last month President Trump signed an executive order designed to fast track both research and access to psychedelic drugs as treatments for mental health illnesses. The most prominent in the order was ibogaine, a drug derived from the root bark of a West African shrub, that has shown some promise…
12 May 17 min
All episodes